ADMA Biologics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-11$20.38 RISE2026-03-26$8.29 PEAK2026-04-24$11.26 134d | -59.3% 105d | Missed | Missed | — | — | +35.8% 29d | Missed |
DROP2025-08-04$19.91 RISE2025-11-06$14.03 PEAK2025-12-11$20.38 129d | -29.5% 94d | Missed | Missed | — | — | +45.3% 35d | Missed |
DROP2025-06-11$21.87 RISE2025-10-07$13.99 PEAK2025-12-11$20.38 183d | -36.0% 118d | Missed | Missed | — | — | +45.7% 65d | Missed |
DROP2024-11-08$22.62 RISE2025-02-27$15.44 PEAK2025-04-28$24.51 171d | -31.7% 111d | Missed | Missed | — | — | +58.7% 60d | Missed |
DROP2024-11-08$22.62 RISE2025-02-25$15.44 PEAK2025-04-28$24.51 171d | -31.7% 109d | Missed | Missed | — | — | +58.7% 62d | Missed |
DROP2024-10-08$20.72 RISE2024-10-21$15.62 PEAK2024-11-08$22.62 31d | -24.6% 13d | Missed | Missed | — | — | +44.8% 18d | Missed |
DROP2024-07-23$13.76 RISE2024-08-05$11.30 PEAK2024-10-08$20.72 77d | -17.9% 13d | Missed | Missed | — | — | +83.4% 64d | Missed |
DROP2023-08-14$4.61 RISE2023-12-11$3.70 PEAK2024-03-08$6.34 207d | -19.7% 119d | Missed | Missed | — | — | +71.4% 88d | Missed |
DROP2023-08-14$4.61 RISE2023-10-23$3.08 PEAK2024-01-09$5.07 148d | -33.2% 70d | Missed | Missed | — | — | +64.6% 78d | Missed |
DROP2023-05-12$4.22 RISE2023-07-12$3.47 PEAK2023-08-14$4.61 94d | -17.8% 61d | Missed | Missed | — | — | +32.9% 33d | Missed |
DROP2022-12-30$3.88 RISE2023-03-22$3.01 PEAK2023-05-12$4.22 133d | -22.4% 82d | Missed | Missed | — | — | +40.2% 51d | Missed |
DROP2022-12-30$3.88 RISE2023-01-19$3.28 PEAK2023-02-07$3.86 39d | -15.5% 20d | Missed | Missed | — | — | +17.7% 19d | Missed |
DROP2022-09-08$2.86 RISE2022-09-29$2.26 PEAK2022-12-22$3.80 105d | -21.0% 21d | Missed | Missed | — | — | +68.1% 84d | Missed |
DROP2022-04-07$2.12 RISE2022-05-11$1.43 PEAK2022-07-08$2.31 92d | -32.5% 34d | Missed | Missed | — | — | +61.5% 58d | Missed |
DROP2022-03-11$1.78 RISE2022-03-23$1.46 PEAK2022-06-17$2.20 98d | -18.0% 12d | Missed | Missed | — | — | +50.7% 86d | Missed |
1–15 / 26 1 / 2 | |||||||
ADMA Biologics faces IVIG headwinds: flat Q1 revenue, cut 2026 guidance, shares down 50% YTD.
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.
In early May 2026, ADMA Biologics reported flat year-on-year quarterly sales of US$114.49 million but sharply higher net income of US$45.33 million and updated its 2026 revenue outlook to a range of US$530 million to US$560 million, while also securing FDA approval to expand ASCENIV’s label to pediatric patients aged two and older. A short seller report accusing ADMA of inflating 2025 revenues through channel stuffing has triggered multiple securities law investigations and raised fresh...
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the best small cap stocks to buy for 10x potential. On May 7, Mizuho lowered the price target on ADMA Biologics, Inc. (NASDAQ:ADMA) to $20 from $24 while maintaining an Outperform rating on the shares. The stock also received a rating update from Canaccord the same day, with the […]
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ADMA, AMTB and APOG have been added to the Zacks Rank #5 (Strong Sell) List on May 14th, 2026.
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best healthcare stocks to buy for the long term. Canaccord cut the price target on ADMA Biologics Inc. (NASDAQ:ADMA) to $18 from $21 on May 7, reiterating a Buy rating on the shares. The firm told investors that fiscal Q1 2026 was a reset quarter for the […]
Block & Leviton is investigating ADMA Biologics, Inc. for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn...
Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.
Block & Leviton is investigating ADMA Biologics, Inc. for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn...
U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.
Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsAdam Grossman - Co-Founder, President, CEO & DirectorP.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ADMA | -24.14% | -51.87% | -56.25% | -59.78% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -27.11% | -46.15% | -52.81% | -72.47% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 14.08M | $126.90M | 0.00% | Added+3.6% | 2026-03-31 |
| CapResearch | fundamental | 11.19M | $100.83M | 0.02% | Added+68.6% | 2026-03-31 |
| Citadel | multi-strat | 3.29M | $29.63M | 0.04% | Added+735.0% | 2026-03-31 |
| TwoSigma | quant | 2.09M | $18.85M | 0.02% | Added+315.0% | 2026-03-31 |
| RenTech | quant | 1.26M | $11.38M | 0.02% | Trimmed-17.6% | 2026-03-31 |
| DEShaw | quant | 560.8K | $5.05M | 0.00% | Added+0.7% | 2026-03-31 |
| Bridgewater | macro | 472.1K | $4.25M | 0.02% | Added+153.2% | 2026-03-31 |
| FidelityFMR | fundamental | 338.9K | $3.05M | 0.00% | Added+12.1% | 2026-03-31 |
| Wellington | fundamental | 95.2K | $857.87K | 0.00% | Trimmed-2.2% | 2026-03-31 |
| TRowePrice | fundamental | 2.22M | $19.97K | 0.00% | Added+2.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 0.18 | — | — |
| 2026-05-06 | 0.20 | 0.17 | -15.25% |
| 2026-02-25 | 0.20 | 0.22 | +7.85% |
| 2025-11-05 | 0.15 | 0.15 | — |
| 2025-08-06 | 0.14 | 0.14 | +7.41% |
| 2025-05-07 | 0.17 | 0.11 | -33.33% |
| 2025-03-03 | 0.15 | 0.14 | -9.33% |
| 2024-11-07 | 0.13 | 0.15 | +15.38% |
| 2024-08-08 | 0.08 | 0.13 | +62.50% |
| 2024-05-09 | 0.05 | 0.08 | +60.00% |
| 2024-02-28 | 0.02 | 0.04 | +153.33% |
| 2023-11-08 | -0.01 | 0.01 | +200.00% |
| 2023-08-09 | -0.02 | -0.02 | +35.32% |
| 2023-05-10 | -0.04 | -0.03 | +29.41% |
| 2023-03-23 | -0.07 | -0.06 | +18.18% |
| 2022-11-09 | -0.07 | -0.08 | -9.10% |